Abstract:There was very little high-level evidence about which radiation therapy (RT) regimen was more effective for prostate cancer after radical prostatectomy (RP). In 2011, we began the randomized, controlled, phase 3 trial to investigate the effect of dose intensified post-operative RT. Patients were randomly assigned to either 66Gy/33f or 72Gy/36f. The aim of current analysis was to compare toxicity, urinary continence recovery and biochemical outcomes. This trial recruited patients who had received RP for a histologically confirmed adenocarcinoma of the prostate, and who had stage pT3-4, positive surgical margins, pN+ or who had rising PSA of 0.2ng/ml following RP. Eligible patients were randomly assigned (1:1) to receive either 66Gy or 72Gy. IG-VMAT techniques was used. The primary endpoint was biochemical progression-free survival (PSA increase of 0.2 ng/ml or greater from the post-RT nadir, a continued rise in PSA despite RT or the initiation of salvage ADT). The second endpoints were acute and late toxicity, and urinary continence recovery. Genitourinary (GU) and gastrointestinal (GI) toxicity was assessed using RTOG-EORTC criteria. Incontinence was assessed by International Consultation on Incontinence Modular Questionnaire Short Form (ICIQ-SF) at start/end of RT and 1 year afterward. Between September 2011 and November 2016, 144 patients were randomly assigned, 71 to 66Gy group and 73 to 72Gy group. The median follow-up time was 42 months (range: 10-71 mos). 3-year biochemical progression-free survival was 73.8% vs. 76.6% in 66Gy vs. 72Gy group. For acute toxicity, no significant differences were seen between the two groups. Acute GU toxicity grade 1 and 2 were reported as 74.6% and 83.6%, 5.6% and 4.4% respectively. Late GU toxicity grade 1 and 2 were 18.3% and 8.2%, 8.5% and 11.0%. Grade 3 GU toxicity was observed in one patient in 72Gy group. For acute GI toxicity, these figures were 78.9% and 84.9%, 11.3% and 8.2%. Late GI grade 1 and 2 were 9.9% and 8.2%, 1.4% and 2.7%. No significant differences between both groups were seen for late GI and GU toxicity. At baseline 48 (33.3%) of patients were incontinent (16.7% mild, 13.9% moderate, 2.8% severe). Of these 48 patients, continence was recovery one year after RT by 33.3% vs. 28.6% with 66Gy vs. 72Gy. 63.0% vs. 66.7% of patients remained stable. Only 2 patients felt more seriously after RT. Our study suggested that dose-intensified RT was associated with low rates of acute and late grade 2-3 GU/GI toxicity, and had no obviously impact on one-year urinary continence recovery. However, the long-term survival outcomes needed to be further explored.

Hypofractionated Radiation Therapy Versus Conventional Radiation Therapy in Patients with Intermediate- to High-Risk Localized Prostate Cancer

Efficacy and adverse effects of hypofractionated radiotherapy versus conventionally fractionated radiotherapy in patients with intermediate-to high-risk localized prostate cancer:a meta-analysis

Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis

Gastrointestinal/genitourinary adverse event after intensity modulated versus three-dimensional primary radiation therapy in the treatment of prostate cancer: systematic review and meta-analysis

Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China

Prospective Phase Ⅱ Trial of Hypofractionated Intensity-Modulated Radiotherapy for Localized Prostate Cancer

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer

Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer

Hypofractionated intensity-modulated radiation therapy for prostate cancer confined to the pelvis: analysis of efficacy and late toxicity

Hypofractionated Volumetric-Modulated Arc Therapy for Localized Intermediate-High Risk Prostate Cancer: a Clinical Analysis

A preliminary toxicity study of different dose fractionation regimens in postoperative radiotherapy for prostate cancer

Photon vs proton hypofractionation in prostate Cancer: A systematic review and meta -analysis

Comparison of Oncological Outcomes Between Radical Prostatectomy and Radiotherapy by Type of Radiotherapy in Elderly Prostate Cancer Patients

Hypo-Fractionated Intensity Modulated Radiotherapy (IMRT) after Prostatectomy: Results of A Prospective Study

Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial

Radiotherapy in localized prostate cancer: a multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients

A Dosimetric Comparison Between Conventional Fractionated and Hypofractionated Image-guided Radiation Therapies for Localized Prostate Cancer

Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial

The feasibility and safety of high-intensity focused ultrasound combined with low-dose external beam radiotherapy as supplemental therapy for advanced prostate cancer following hormonal therapy.

Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer

Toxicity And Biochemical Outcomes After Dose Intensified Post-Operative Radiation Therapy For Prostate Cancer: A Randomized, Controlled, Phase 3 Trial